ABSTRACT
Objective To study the effect of carvedilol on heart rate variability and plasma N-terminal brain natriuretic peptide(NT-proBNP) in patients with chronic heart failure.Methods 106 patients with chronic heart fail-ure were randomly divided into the two groups ..53 patients in the control group were treated by the conventional ther-apy plus metoprolol ,while 53 patients in the observation group were treated by the conventional therapy plus carve -dilol.They were treated for six months .Heart rate variability and plasma NT-proBNP were measured before and after treatment in the two groups .Results The total effective rate of the control group was 83.0%,which was significantly lower than 94.3% of the observation group (χ2 =6.26,P0.05).After treatment,SDNN,SDANN,RMSSD and PNN50 were significantly increased (t=3.095,9.184,3.622,4.302,2.261, 4.522,2.921,2.992,P <0.05 or P <0.01).Compared with the control group,those in the observation group increased more significantly (t=8.065,3.116,3.209,2.171,P<0.05 or P<0.01).After treatment,plasma NT-proBNP were significantly decreased in the two groups (t=7.093,9.773,all P<0.01).Compared with the control group,plasma NT-proBNP of the observation group decreased more significantly (t=4.773,P<0.01).Conclusion Carvedilol can more significantly improve heart rate variability and plasma NT-proBNP in patients with chronic heart failure.
ABSTRACT
Objective To study the effect of ulinastatin on serum C-reactive protein (CRP) and exhaled nitric oxide(FeNO) in patients with bronchial asthma.Methods 98 patients with bronchial asthma were randomly divided into the control group (n =49 cases) and the observation group (n =49 cases).The patients in the control group were treated through the conventional treatment,while the patients in the observation group were treated through the conventional treatment plus ulinastatin.Pulmonary function,asthma symptom scores,serum CRP and FeNO were measured before and after treatment.Results FEV1％ and predicted PEF values after treatment were significantly increased (t =4.720,8.112,3.724,6.723,all P ＜ 0.05).Compared with the control group,the observation group after treatment increased more significantly (t =3.102,4.002,all P ＜ 0.05).After the treatment,the asthma symptom scores were significantly decreased (t =2.190,6.021,all P ＜ 0.05).Compared with the control group,the asthma symptom scores of the observation group significantly decreased (t =2.620,P ＜ 0.05).After treatment,FeNO and CRP were significantly decreased (t =9.124,13.076,5.772,7.064,all P ＜ 0.01).Compared with the control group,FeNO and CRP of the observation group significantly decreased (t =3.060,5.401,all P ＜ 0.05).Conclusion Ulinastatin can significantly decrease serum CRP and FeNO in patients with bronchial asthma.
ABSTRACT
Objective To study the impact of alprostadil on serum high-sensitivity C-reactive protein ( hs-CRP) and troponin I( cTnI) in patients with diastolic heart failure.Methods 92 patients with diastolic heart failure were randomly divided into the two groups,the control group and the observation group,46 cases in each group.The control group used the conventional treatment and the observation group on the basis of conventional therapy plus al-prostadil.Two groups were treated for 4 weeks.They were measured filling velocity ratio (E/A) in patients with early and late peak atrial contraction,stroke volume (SV),left ventricular end-diastolic diameter (LVEDD),6min walking distance and serum hs-CRP, cTnI before and after treatment.Results There were no significant difference about LVEDD,E/A and SV(t=0.,0.261,0.445,all P>0.05).After treatment for four weeks,LVEDD were (53.1 ± 5.1)mm and (47.3 ±4.7)mm,LVEDD of the two groups had significantly decreased (t=4.601,9.331,P0.05).After 4 weeks of treatment,the serum hs-CRP,cTnI were significantly lower in both groups (t=3.612,8.772,2.924, 5.164,P<0.05,P<0.01),and compared with the control,the observation group reduced more significantly (t=3.061,7.114,P<0.05).Conclusion Alprostadil can decrease serum hs-CRP and cTnI of patients with diastolic heart failure.